Seres Therapeutics (MCRB) Expected to Post Earnings on Wednesday

Seres Therapeutics (NASDAQ:MCRB) is expected to be posting its Q3 2026 results before the market opens on Wednesday, November 4th. Analysts expect Seres Therapeutics to announce earnings of ($1.0050) per share and revenue of $6.35 million for the quarter. Parties may review the information on the company’s upcoming Q3 2026 earnings report page for the latest details on the call scheduled for Wednesday, November 11, 2026 at 8:30 AM ET.

Seres Therapeutics (NASDAQ:MCRB) last released its quarterly earnings results on Wednesday, August 5th. The biotechnology company reported $0.47 EPS for the quarter, topping analysts’ consensus estimates of ($2.18) by $2.65. The firm had revenue of $0.74 million during the quarter, compared to analysts’ expectations of $0.18 million. Seres Therapeutics had a negative net margin of 1,192.94% and a negative return on equity of 114.82%. On average, analysts expect Seres Therapeutics to post ($6.33) EPS for the current fiscal year and ($2.06) EPS for the next fiscal year.

Seres Therapeutics Trading Up 3.4%

Shares of NASDAQ:MCRB opened at $1.83 on Tuesday. Seres Therapeutics has a 12 month low of $1.68 and a 12 month high of $29.98. The firm’s 50-day moving average is $3.56 and its 200 day moving average is $7.12.

Analyst Ratings Changes

Several research analysts have issued reports on the company. Wall Street Zen upgraded Seres Therapeutics from a “sell” rating to a “hold” rating in a research report on Saturday, August 8th. Weiss Ratings cut Seres Therapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Friday, September 18th. Two analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the company currently has a consensus rating of “Hold” and a consensus price target of $17.00.

About Seres Therapeutics

Seres Therapeutics, Inc is a biotechnology company focused on developing live biotherapeutic products designed to restore the function of the human microbiome. The company’s platform uses defined communities of microorganisms rather than conventional fecal material to address diseases associated with microbiome disruption.

Seres’ lead product, VOWST (fecal microbiota spores, live-brpk), was approved by the U.S. Food and Drug Administration in 2023 to prevent the recurrence of Clostridioides difficile infection in adults following antibacterial treatment.